Low dose naltrexone and the growing evidence across chronic conditions

LDN has now been explored across a wide range of chronic pain, inflammatory, neurological, skin, gastrointestinal and post-infectious conditions. Early trials, case series and clinical experience point to encouraging results in several of these areas, and LDN is generally well tolerated. However, much of the evidence is still at an early stage, and larger, rigorous placebo-controlled trials are needed before firm conclusions can be drawn. Standard-dose naltrexone is licensed for alcohol and opioid dependence, whereas LDN, usually around 1–5 mg daily, is used off-label. [1], [2]

This article sets out where LDN has been studied, what the results show so far, and why further research matters.

Key takeaways

• Low-dose naltrexone is naltrexone at around one-tenth of the usual dose, typically 1–5 mg daily, and is used off-label in the UK. [1]
• Fibromyalgia has the strongest evidence so far, with a 2024 meta-analysis of four placebo-controlled trials finding reduced pain scores. [4]
• Encouraging early results have also been reported in neuropathic pain, Crohn’s disease, MS-related spasticity, several skin conditions and Long COVID. [10], [19], [24], [32], [37]
• LDN is generally well tolerated, but it can interfere with opioid pain medicines, so prescriber advice is essential. [2], [46]
• Larger, rigorous placebo-controlled trials are needed to confirm which conditions and patients benefit most. [2], [18]

What is low-dose naltrexone and how might it work?

LDN usually refers to doses of around one-tenth of the standard naltrexone dose, often 1–5 mg daily, although studies vary in the exact range used. [1] At these low doses, naltrexone appears to behave quite differently from the standard dose.

Researchers have proposed two main mechanisms. First, a brief blockade of opioid receptors may prompt the body to increase its own endogenous opioid signalling. Second, LDN may calm immune and glial-cell inflammatory pathways in the nervous system, which are thought to drive many chronic pain and inflammatory states. [2], [3] These mechanisms are biologically plausible and help explain why LDN has been explored across so many seemingly unrelated conditions. They are, however, still being confirmed.

Conditions where low-dose naltrexone has been studied

Fibromyalgia and chronic pain

Fibromyalgia has the strongest evidence base of any LDN indication. A 2024 meta-analysis pooling four placebo-controlled trials with 222 participants found that LDN reduced pain scores compared with placebo. [4] Overall impact scores (FIQR) and pain-catastrophising scores did not differ significantly, so the benefit appears to centre on pain itself. [4] This builds on an earlier randomised, double-blind crossover trial that also reported lower daily pain with LDN. [5] Not every study has replicated these findings, which is why larger trials remain a priority. [2]

Beyond fibromyalgia, clinical studies and case reports describe use in complex regional pain syndrome (CRPS), painful diabetic neuropathy and other neuropathic pain, multiple-sclerosis-related pain, chronic low-back pain, post-traumatic trigeminal neuropathic pain and neuropathic corneal pain. [6], [7], [8], [9], [10] In the corneal pain study, investigators described LDN as effective and well tolerated. [10] A case report also described its use for neuropathic pain after an electrical burn injury. [11]

Interestingly, a retrospective clinic series found that patients with neuropathic pain or CRPS were more likely to report relief than those with spondylosis. [13] This suggests LDN may suit some pain types better than others, a finding that future trials could explore. Small case reports and series in CRPS add to this picture. [12]

LDN has also been used for burning mouth syndrome, headache or migraine, interstitial-cystitis-associated pain, chronic pelvic pain and vulvodynia, with improvements reported in individual cases and small series. [14], [15], [16], [17] A 2023 scoping review of centralised pain conditions found a substantial body of case reports and narrative reviews, alongside a few randomised trials. Its authors called for larger trials with standardised dosing. [18]

Crohn’s disease and inflammatory bowel disease

Crohn’s disease has been tested in small placebo-controlled trials. A Cochrane review identified two studies with 46 participants in total. In the adult trial, clinical response and endoscopic response favoured LDN, although the difference in clinical remission did not reach statistical significance. The review rated the evidence as low quality and too limited for firm conclusions. [19]

Observational reports in broader inflammatory bowel disease (IBD) and a case report in ulcerative colitis add to this early signal. [20], [21] LDN is not a substitute for standard IBD treatment, and anyone with IBD should continue established therapy under specialist care.

Other digestive conditions in the literature include irritable bowel syndrome (IBS) and symptomatic mesenteric panniculitis. The IBS work sets out a scientific rationale for LDN, and the mesenteric panniculitis pilot involved three patients. [22], [23]

Neurological, autoimmune and rheumatological conditions

Multiple sclerosis (MS), including primary progressive MS and clinically isolated syndrome, has been explored in pilot and observational work. In a six-month pilot of 40 people with primary progressive MS, LDN was well tolerated and investigators reported a reduction in spasticity. [24] The study was designed mainly to assess safety, so it does not show whether LDN slows disability progression.

A rheumatology review describes case reports and observational data in Sjögren’s syndrome, rheumatoid arthritis, systemic sclerosis (scleroderma) and dermatomyositis. [25] Sarcoidosis and stiff-person syndrome have also featured in case-level reports describing symptom improvement. [26], [27]

Skin and hair conditions

Dermatology is one of the most active areas of LDN interest. Reviews in leading dermatology journals cover Hailey–Hailey disease, Darier disease, psoriasis, lichen planus (including nail disease), lichen planopilaris, hidradenitis suppurativa, dermatomyositis-related skin symptoms, and itch associated with skin or systemic disorders. [28], [29], [30], [31]

Hailey–Hailey disease stands out, with a recurring series of favourable case reports. [32] Psoriasis evidence includes case reports and a five-person pilot study. [33], [34] LDN has also been discussed for scalp discomfort linked to hair loss and for body-focused repetitive behaviours such as skin-picking. [31], [35] These applications are promising but still at the case-report or review stage.

ME/CFS, Long COVID and other chronic syndromes

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-COVID condition (Long COVID) are among the most closely watched newer uses. A retrospective ME/CFS clinical series reported that many patients perceived an improvement, although the study had no control group. [36]

For Long COVID, a 2025 systematic review found four observational before-and-after studies involving 155 people. Pooled analyses showed improvements in symptoms, but there were no randomised controlled trials and the authors rated the certainty of evidence as low. [37] Gulf War illness has also been mentioned in the LDN literature. [38]

Dysautonomia, including postural orthostatic tachycardia syndrome (POTS), has been explored in a small chart review. Some patients reported improved pain, although autonomic symptom scores did not change significantly. [39] Endometriosis, idiopathic hypereosinophilic syndrome and mesenteric panniculitis have also been discussed, mainly through hypotheses, small pilots and individual cases. [23], [40], [41]

Mental health and behaviour

Depression, autism, dissociative or trauma-related symptoms and excoriation (skin-picking) disorder have all been proposed as areas for LDN research. Early reports include a small treated group with dissociative symptoms and a single case of excoriation disorder. [31], [42], [43] These are early findings that warrant formal study.

Cancer

LDN has generated scientific interest as a possible immune-modulating adjunct in cancer care, supported mainly by preclinical work and limited clinical reports. [44] It is not an established cancer treatment and should never replace standard oncology care. Separately, a 2025 retrospective case series reported initial safety and effectiveness of LDN for refractory cancer-related pain, which is a symptom-management question rather than evidence of anti-tumour benefit. [45]

Safety and tolerability

One of the consistent themes across the literature is that LDN is generally well tolerated at low doses. [2] This favourable safety profile is part of why clinicians and researchers continue to explore it in conditions where existing options are limited.

LDN is an opioid antagonist, however. Anyone taking opioid pain medicines, or likely to need opioid pain relief (for example, before planned surgery), should discuss LDN with a prescriber before starting it, as it can interfere with opioid treatment. [46]

Why larger placebo-controlled trials are needed

The research so far is encouraging, but most of it comes from small trials, open-label studies, case series and individual reports. Chronic pain and fatigue conditions also tend to show strong placebo responses, so well-designed placebo-controlled trials are essential to confirm how much benefit LDN truly adds. Dosing has also varied between studies, which makes results harder to compare.

A 2026 narrative review concluded that LDN is generally tolerated but that current evidence does not yet support routine clinical use. It suggested that, where LDN is considered in treatment-resistant cases, its uncertain efficacy and experimental status should be made clear. [2] As naltrexone is an established, off-patent medicine, there is limited commercial incentive to fund large trials, which is one reason the evidence has lagged behind clinical interest.

Larger, rigorous, placebo-controlled trials with standardised dosing would help confirm which patients are most likely to benefit, and in which conditions.

Is low-dose naltrexone right for me?

In the UK, LDN is a prescription-only medicine used off-label. Whether it is suitable depends on your condition, your medical history and any other medicines you take, so the decision should always be made with a prescriber who can weigh up the current evidence with you.

Disclaimer

Disclaimer: This information is for education only and isn’t a substitute for personal medical advice. Always follow your prescriber’s instructions.

References

[1]       K. Toljan and B. Vrooman, “Low-dose naltrexone (LDN): review of therapeutic utilization,” Medical Sciences, 2018, doi: 10.3390/medsci6040082.

[2]       A. H. K. Gouda, N. E. C. Aitcheson, and K. J. Steadman, “Low-dose naltrexone: What is the evidence? A narrative review,” Advances in Therapy, 2026, doi: 10.1007/s12325-026-03612-5.

[3]       J. Younger, L. Parkitny, and D. McLain, “The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain,” Clinical Rheumatology, 2014, doi: 10.1007/s10067-014-2517-2.

[4]       A. D. Vatvani, P. Patel, T. I. Hariyanto, and T. A. Yanto, “Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: A systematic review and meta-analysis of randomized controlled trials with trial sequential analysis,” pp. 367–378, 2024, doi: 10.3344/kjp.24202.

[5]       J. Younger, N. Noor, R. McCue, and S. Mackey, “Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels,” Arthritis and Rheumatism, 2013, doi: 10.1002/art.37734.

[6]       K. M. Bostick, A. G. McCarter, and D. Nykamp, “The use of low-dose naltrexone for chronic pain,” The Senior Care Pharmacist, 2019, doi: 10.4140/tcp.n.2019.43.

[7]       D. Hota, A. Srinivasan, P. Dutta, A. Bhansali, and A. Chakrabarti, “Off-label, low-dose naltrexone for refractory painful diabetic neuropathy,” Pain Medicine, 2016, doi: 10.1093/pm/pnv009.

[8]       B. Ghai, D. Bansal, D. Hota, and C. S. Shah, “Off-label, low-dose naltrexone for refractory chronic low back pain,” Pain Medicine, 2014, doi: 10.1111/pme.12345.

[9]       S. Ananthan, G. Heir, and O. Korczniewska, “Use of low-dose naltrexone in the management of post-traumatic trigeminal neuropathic pain: A retrospective case series,” Quintessence International, 2025, doi: 10.3290/j.qi.b6335903.

[10]    G. Dieckmann, M. C. Ozmen, S. Cox, R. Engert, and P. Hamrah, “Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain,” The Ocular Surface, 2021, doi: 10.1016/j.jtos.2020.12.003.

[11]    M. Cowling and M. Poliak-Tunis, “(367) Low dose naltrexone for neuropathic pain related to an electrical burn injury: A case study,” Journal of Pain, 2019, doi: 10.1016/j.jpain.2019.02.063.

[12]    P. Chopra and M. S. Cooper, “Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN),” Journal of Neuroimmune Pharmacology, 2013, doi: 10.1007/s11481-013-9451-y.

[13]    A. M. McKenzie-Brown, D. W. Boorman, K. R. Ibanez, E. Agwu, and V. Singh, “Low-dose naltrexone (LDN) for chronic pain at a single institution: A case series,” Journal of Pain Research, 2023, doi: 10.2147/jpr.s389957.

[14]    L. Sangalli and C. S. Miller, “Low-dose naltrexone for treatment of burning mouth syndrome,” Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2022, doi: 10.1016/j.oooo.2022.04.048.

[15]    D. L. Neuman and A. L. Chadwick, “Utilization of low-dose naltrexone for burning mouth syndrome: A case report,” A&A Practice, 2021, doi: 10.1213/xaa.0000000000001475.

[16]    J. Jaros and P. Lio, “Low dose naltrexone in dermatology,” Journal of Drugs in Dermatology, 2019. Available: https://pubmed.ncbi.nlm.nih.gov/30909326

[17]    R. T. Sullender, R. Silverstein, D. M. Goodwin, A. McClurg, and E. T. Carey, “Low-dose naltrexone as a treatment for vulvodynia: A case series,” Case Reports in Women’s Health, 2024, doi: 10.1016/j.crwh.2024.e00677.

[18]    A. Rupp, E. E. Young, and A. L. Chadwick, “Low-dose naltrexone’s utility for non-cancer centralized pain conditions: A scoping review,” Pain Medicine, 2023, doi: 10.1093/pm/pnad074.

[19]    C. Parker, T. M. Nguyen, D. Segal, J. Macdonald, and N. Chande, “Low dose naltrexone for induction of remission in Crohn’s disease,” Cochrane Database of Systematic Reviews, 2018, doi: 10.1002/14651858.CD010410.pub3.

[20]    M. R. K. L. Lie et al., “Low dose naltrexone for induction of remission in inflammatory bowel disease patients,” Journal of Translational Medicine, 2018, doi: 10.1186/s12967-018-1427-5.

[21]    S. Kais, “P-015 YI Low-dose naltrexone therapy improves active ulcerative colitis,” Inflammatory Bowel Diseases, 2013, doi: 10.1097/01.mib.0000438656.15392.e8.

[22]    R. Kariv, “Low-dose naltrexone for the treatment of irritable bowel syndrome,” The American Journal of Gastroenterology, 2003, doi: 10.1016/s0002-9270(03)01577-6.

[23]    C. Melitas, G. Roginsky, A. Alexoff, and E. D. Ehrenpreis, “An open label trial of low-dose naltrexone (LDN) for symptomatic mesenteric panniculitis, presidential poster: 1005,” The American Journal of Gastroenterology, 2015, doi: 10.14309/00000434-201510001-01005.

[24]    M. Gironi et al., “A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis,” Multiple Sclerosis, vol. 14, pp. 1076–1083, 2008, doi: 10.1177/1352458508095828.

[25]    J. F. de Carvalho and T. L. Skare, “Low-dose naltrexone in rheumatological diseases,” Mediterranean Journal of Rheumatology, 2023, doi: 10.31138/mjr.34.1.1.

[26]    L. Weinstock, T. L. Myers, and A. S. Shetty, “Low-dose naltrexone for the treatment of sarcoidosis,” Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, doi: 10.36141/svdld.v34i2.5303.

[27]    M. W. Zappaterra, E. Shouse, and R. Levine, “Low-dose naltrexone reduces symptoms in stiff-person syndrome,” Medical Hypotheses, 2020, doi: 10.1016/j.mehy.2019.109546.

[28]    M. H. Zhou, D. Elston, B. W. Morrison, and S. Lipner, “Low-dose naltrexone for treatment of dermatologic conditions: A clinical review,” Journal of the American Academy of Dermatology, 2025, doi: 10.1016/j.jaad.2025.09.028.

[29]    C. Ekelem, M. Juhász, P. Khera, and N. Mesinkovska, “Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: A systematic review,” JAMA Dermatology, 2019, doi: 10.1001/jamadermatol.2018.4093.

[30]    E. R. Bray and B. W. Morrison, “Low-dose naltrexone use in biopsy-proven lichen planus of the nails,” JAMA Dermatology, 2024, doi: 10.1001/jamadermatol.2024.4098.

[31]    K. J. Varghese, X. Yan, and F. Cao, “Low-dose naltrexone for excoriation disorder,” Cureus, 2024, doi: 10.7759/cureus.55336.

[32]    L. N. Albers, J. Arbiser, and R. Feldman, “Treatment of Hailey-Hailey disease with low-dose naltrexone,” JAMA Dermatology, 2017, doi: 10.1001/jamadermatol.2017.2446.

[33]    E. P. B. Monasterio, “Low-dose naltrexone: An alternative treatment for erythrodermic psoriasis,” Cureus, 2019, doi: 10.7759/cureus.3943.

[34]    H. M. E. Fakahany, D. A. Abdelhamed, and M. R. Ibrahim, “Low dose naltrexone in treatment of psoriasis: A pilot study,” Minia Journal of Medical Research, 2025, doi: 10.21608/mjmr.2025.410771.2066.

[35]    V. D. Tortelly, T. De Mattos, L. S. de Albuquerque Fernandes, B. E. M. Nunes, and D. F. Melo, “Low-dose naltrexone: A novel adjunctive treatment in symptomatic alopecias?” Dermatology Online Journal, 2019, doi: 10.5070/d3258045142.

[36]    O. Polo, P. Pesonen, and E. Tuominen, “Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS),” Fatigue: Biomedicine, Health & Behavior, 2019, doi: 10.1080/21641846.2019.1692770.

[37]    O. Byambasuren, T. Atkins, S. Baptista, P. Glasziou, and S. Chakraborty, “Effect of low dose naltrexone for long COVID: A systematic review,” medRxiv, 2025, doi: 10.1101/2025.09.09.25335451.

[38]    M. Bolton, B. P. Chapman, and H. van Marwijk, “Low-dose naltrexone as a treatment for chronic fatigue syndrome,” BMJ Case Reports, 2020, doi: 10.1136/bcr-2019-232502.

[39]    N. Zapata, E. Georgiadi, C. Cantrell, R. G. Rilinger, M. Levine, and R. Wilson, “Low-dose naltrexone for managing pain and autonomic symptoms in patients with dysautonomia,” Cureus, 2025, doi: 10.7759/cureus.86538.

[40]    O. Golianovskyi, O. O. Andrienko, O. V. Furman, and P. Boyle, “Prospective of low dose naltrexone use in treatment of autoimmune pathology and endometriosis,” Reproductive Endocrinology, 2020, doi: 10.18370/2309-4117.2020.55.53-57.

[41]    F. Rodriguez, M. Carvalho, and F. Banov, “Case study: Personalized oral low-dose naltrexone titration for pain management,” International Journal of Pharmaceutical Compounding, 2023. Available: https://pubmed.ncbi.nlm.nih.gov/38100664

[42]    N. Brown and J. Panksepp, “Low-dose naltrexone for disease prevention and quality of life,” Medical Hypotheses, 2009, doi: 10.1016/j.mehy.2008.06.048.

[43]    W. Pape and W. Wöller, “[Low dose naltrexone in the treatment of dissociative symptoms],” Der Nervenarzt, 2015, doi: 10.1007/s00115-014-4015-9.

[44]    M. Ciwun, A. Tankiewicz-Kwedlo, and D. Pawlak, “Low-dose naltrexone as an adjuvant in combined anticancer therapy,” Cancers, 2024, doi: 10.3390/cancers16061240.

[45]    A. Malik, A. L. Ye, and M. Chung, “Low dose naltrexone for refractory cancer pain: Case series of initial safety and effectiveness,” Journal of Pain and Symptom Management, 2025, doi: 10.1016/j.jpainsymman.2025.08.015.

[46]    H. Huang, D. C. Ijebuonwu, R. Whitney, and K. Wyatt-Thompson, “Low-dose naltrexone for pediatric chronic pain and inflammatory states: Perioperative considerations,” Paediatric Anaesthesia, 2025, doi: 10.1111/pan.15070.